Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize
Read MoreNovo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize
Read MoreAware uses AI to analyze companies' employee messages across Slack, Microsoft Teams, Zoom and other communications services. Source link
Read MoreThe JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer
Read MoreMany biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read MoreNext year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by
Read MoreOprah Winfrey has changed her mind on weight loss drugs and others have, too. What's ahead for the category in
Read More2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance
Read MoreThe rise of Ozempic and a health conscious consumer has the alcohol industry on the defensive. Yet, there's still opportunity
Read MoreHere are the biggest calls on Wall Street on Source link
Read More